Immunological Characteristics of COVID-19 Patients and Determination of Neutralizing Antibodies Against SARS-CoV-2 Virus
Immunological Characteristics of COVID-19 Patients and Determination of Neutralizing Antibodies Against SARS-CoV-2 Virus
The study will look at the immunological characteristics of COVID-19 patients and determine neutralizing antibodies against SARS-CoV-2 virus.
The immunogram (quantitative TBNK immunophenotipisation) will be performed by flow cytometry, the antibody response will be determined by IVD ELISa.
Clinical biochemical and immunochemical (ECLIA) tests (including IL-6) will be performed on Cobas analyzers. Hemogram with differential blood picture will be performed with a hematology analyzer Sysmex XN 3100, examination of blood smears with CellaVision system or. microscope. Coagulation tests will be performed on BCS XP analyzers.
An in-house system for the analysis of SARS-CoV-2 virus fusion inhibitors on human cells will be used to detect the ability of antibodies from patients' serum to neutralize the virus and thus potential protection against re-infection. The system is quantitative, meaning that the titer of such antibodies could be determined, and thus the potential level of protection would be evaluated.
Inclusion Criteria:
Provide written consent before being included in the essay.
Positive cases of COVID-19 (based on polymerase chain reaction or positive antigen test for SARS-CoV-2).
Exclusion Criteria:
Patients who are unable to give consent or who are unable to follow up will be excluded.
peter.korosec@klinika-golnik.si042569432 ext. +386
gregor.ostanek@klinika-golnik.si42569500 ext. +386
Golnik, 4204, Slovenia
peter.korosec@klinika-golnik.si4 25 69 432 ext. +386